FDA Issues Warning About Rare but Serious Liver Injury With the Use of Fezolinetant (VEOZAH) for Hot Flashes Due to Menopause
View all alerts
Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

BRISTOL-MEYERS SQUIBB ANNOUNCES IT WILL NO LONGER SHIP WIDELY-USED ANTIDEPRESSANT SERZONE



May 20, 2004

Bristol-Myers Squibb (BMS) announced today that as of June 14, it will no longer ship its widely used antidepressant Serzone. Although stating this is being done for “business” reasons, this is questionable because retail sales of Serzone topped $100 million in 2003. Perhaps the real reason is the liver toxicity of the drug, which has brought massive litigation against the company.

To read the complete press release, follow this link:  http://www.citizen.org/pressroom/rel...

May 20, 2004

Bristol-Myers Squibb (BMS) announced today that as of June 14, it will no longer ship its widely used antidepressant Serzone. Although stating this is being done for “business” reasons, this is questionable because retail sales of Serzone topped $100 million in 2003. Perhaps the real reason is the liver toxicity of the drug, which has brought massive litigation against the company.

To read the complete press release, follow this link:  http://www.citizen.org/pressroom/release.cfm?ID=1716

Disclaimer

The information on this website is not intended to substitute for professional medical advice, diagnosis, or treatment. Consult your doctor before changing or discontinuing any medication.